Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
about
Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.Identification of an IL-1-induced gene expression pattern in AR PCa cells that mimics the molecular phenotype of AR PCa cells
P2860
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@ast
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@en
type
label
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@ast
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@en
prefLabel
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@ast
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@en
P2093
P2860
P1433
P1476
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
@en
P2093
Conor C Lynch
David Basanta
Jeremy S Frieling
P2860
P304
P356
10.1177/107327481502200114
P577
2015-01-01T00:00:00Z